<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686227</url>
  </required_header>
  <id_info>
    <org_study_id>HU3643</org_study_id>
    <nct_id>NCT04686227</nct_id>
  </id_info>
  <brief_title>Prevalence of Uterine Malformations in Newly Married Unselected Population</brief_title>
  <official_title>Prevalence of Uterine Malformations in Newly Married Unselected Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hacettepe University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterine malformation is occur due to the abnormal development of Mullerian canal during&#xD;
      embryogenesis and it is known that it reduces the fertility and live birth rate and also&#xD;
      increases the abortion and preterm birth rate. There are different classification methods&#xD;
      have been used for defining the uterine malformations. The most common used classification&#xD;
      method in the World is American Society of Reproductive Medicine (ASRM)'s system. In addition&#xD;
      European Society of Human Reproduction and Embryology (ESHRE) and European Society for&#xD;
      Gynaecological Endoscopy (ESGE) developed a new classification system. ASRM Uterine&#xD;
      malformation Classification which is used for diagnosis and treatment of uterine&#xD;
      malformations in our clinic is subdivided into 7 titles:&#xD;
&#xD;
        1. Agenesis or Hypoplasia -(a. Vaginal b. Cervical c. Fundal d. Tubal e. Combine)&#xD;
&#xD;
        2. Unicornuate -(a. Communicating Horn b. Non-Communicating Horn c. No Cavity d. No Horn)&#xD;
&#xD;
        3. Uterus Didelphus&#xD;
&#xD;
        4. Bicornuate Uterus-(a. Complete b. Partial)&#xD;
&#xD;
        5. Uterine Septum- (a. Complete b. Partial)&#xD;
&#xD;
        6. Arcuate Uterus&#xD;
&#xD;
        7. Diethylstilboestrol (DES) Related&#xD;
&#xD;
      The diagnosis of some of the uterine malformations have been done by using two dimensional&#xD;
      (2D) ultrasonography, hysterosalphingography or surgically (laparoscopy or laparotomy)&#xD;
      traditionally. A non-invasive procedure is required for the diagnosis of the uterine&#xD;
      malformation, which is evaluating both the uterine contour and endometrial cavity.&#xD;
&#xD;
      In recent years frequently used three dimensional (3D) ultrasound is a non-invasive and quick&#xD;
      diagnostic technique, and also it is sensitive as MRI. In hospital based case control&#xD;
      studies, the frequency of uterine malformation was generally around 6%, while it was 8% in&#xD;
      infertile patients and 12% in patients with abortion. However, there is a lack of prospective&#xD;
      studies investigating the prevalence of uterine anomalies, fertility potential and effects on&#xD;
      pregnancy outcomes in unselected patient groups in the literature. Therefore, at the high&#xD;
      level evidence, there is no evidence that these anomalies affect fertility and pregnancy&#xD;
      outcomes and should be corrected. In this study it was aimed to investigate the effects of&#xD;
      uterine malformations on fecundability and pregnancy outcomes by evaluating the uterine&#xD;
      morphology with 3D ultrasonography and calling for control purposes at the 1st and 2nd years&#xD;
      of newly married women between the ages of 18-40.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a prospective observational study. As it was mentioned above, it&#xD;
      was aimed to investigate the effects of uterine malformations on fecundability and pregnancy&#xD;
      outcomes by evaluating the uterine morphology with 3D ultrasonography and calling for control&#xD;
      purposes at the 1st and 2nd years of newly married women between the ages of 18-40. Firstly a&#xD;
      template flyer's designed to call the newly married women to our study. To be able to explain&#xD;
      the study and call the participants officially, official permission's got from the municipal&#xD;
      leading the wedding hall nearby the hospital (In Turkey, wedding halls are managed by the&#xD;
      municipality covering their locations. As it's needed, the document can be added.). A&#xD;
      scholarship student will explain the study and invite the couples. First and second year&#xD;
      After the ultrasound, the participants will be called by phone to ask unprotected sex period;&#xD;
      if conceived, outcomes of pregnancy (miscarriage, preterm birth, term birth, malpresentation&#xD;
      etc.). Then the data will be worked on SPSS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of uterine malformations</measure>
    <time_frame>1 year after inclusion of last participant</time_frame>
    <description>prevalence of uterine malformations in study population according to ASRM/ESHRE classifications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>spontaneous fecundability</measure>
    <time_frame>1 year after inclusion of last participant</time_frame>
    <description>1 year fecundability rate in subgroup of malformations and normal uterus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pregnancy outcomes</measure>
    <time_frame>During the pregnancy</time_frame>
    <description>Rate of miscarriage, preterm birth, and malpresentation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>1 year</time_frame>
    <description>Having a live birth in all subgroups of uterine malformations and normal uterus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparing of infertility rates</measure>
    <time_frame>1 year</time_frame>
    <description>comparing of infertility rates between normal uterus population and every subgroup of uterine malformations</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Group-1, women with normal uterus</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group-2, women with any uterine malformations</arm_group_label>
    <description>Group-2 is going to be sub-grouped according to ASRM and ESHRE classifications</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>3D Ultrasound</intervention_name>
    <description>Newly married women between the ages of 18-40 will be evaluated by 3D ultrasonography about the uterine morphology</description>
    <arm_group_label>Group-1, women with normal uterus</arm_group_label>
    <arm_group_label>Group-2, women with any uterine malformations</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Newly married women between the ages of 18-40&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Husband is under 45 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Azospermia&#xD;
&#xD;
          -  Women with Premature Ovarian Failure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sezcan Mumusoglu, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sezcan Mumusoglu, Assoc. Prof.</last_name>
    <phone>+905326404673</phone>
    <email>sezcanmumusoglu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hacettepe UniversityHacettepe University School of Medicine, Department of Ob/Gyn</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sezcan Mumusoglu, Assoc. Prof.</last_name>
      <phone>+905326404673</phone>
      <email>sezcanmumusoglu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gurkan Bozdag, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sezcan Mumusoglu, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali Can Gunes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruya Tez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nuseybe Artiran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Chan YY, Jayaprakasan K, Tan A, Thornton JG, Coomarasamy A, Raine-Fenning NJ. Reproductive outcomes in women with congenital uterine anomalies: a systematic review. Ultrasound Obstet Gynecol. 2011 Oct;38(4):371-82. doi: 10.1002/uog.10056. Review.</citation>
    <PMID>21830244</PMID>
  </reference>
  <reference>
    <citation>Raga F, Bauset C, Remohi J, Bonilla-Musoles F, Simón C, Pellicer A. Reproductive impact of congenital Müllerian anomalies. Hum Reprod. 1997 Oct;12(10):2277-81.</citation>
    <PMID>9402295</PMID>
  </reference>
  <reference>
    <citation>Rackow BW, Arici A. Reproductive performance of women with müllerian anomalies. Curr Opin Obstet Gynecol. 2007 Jun;19(3):229-37. Review.</citation>
    <PMID>17495638</PMID>
  </reference>
  <reference>
    <citation>Tomazevic T, Ban-Frangez H, Ribic-Pucelj M, Premru-Srsen T, Verdenik I. Small uterine septum is an important risk variable for preterm birth. Eur J Obstet Gynecol Reprod Biol. 2007 Dec;135(2):154-7. Epub 2006 Dec 19.</citation>
    <PMID>17182166</PMID>
  </reference>
  <reference>
    <citation>Graupera B, Pascual MA, Hereter L, Browne JL, Úbeda B, Rodríguez I, Pedrero C. Accuracy of three-dimensional ultrasound compared with magnetic resonance imaging in diagnosis of Müllerian duct anomalies using ESHRE-ESGE consensus on the classification of congenital anomalies of the female genital tract. Ultrasound Obstet Gynecol. 2015 Nov;46(5):616-22. doi: 10.1002/uog.14825. Epub 2015 Oct 5.</citation>
    <PMID>25690307</PMID>
  </reference>
  <reference>
    <citation>Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org; Practice Committee of the American Society for Reproductive Medicine. Uterine septum: a guideline. Fertil Steril. 2016 Sep 1;106(3):530-40. doi: 10.1016/j.fertnstert.2016.05.014. Epub 2016 May 25. Review.</citation>
    <PMID>27235766</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hacettepe University</investigator_affiliation>
    <investigator_full_name>Sezcan Mumusoglu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Uterine Malformations</keyword>
  <keyword>Fertility</keyword>
  <keyword>Infertility</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Miscarriage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

